Skip to content

Opening book details…

Can I read L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma on EtoBox?

L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma by Shinji Tsutsumi; Satoko Morohashi; Yasuyuki Kudo; Harue Akasaka; Hiroshi Ogasawara; Masashi Ono; Kaori Takasugi; Keinosuke Ishido; Kenichi Hakamada; Hiroshi Kijima is a Medicine article available to read on EtoBox.

What is L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma about?

## Abstract ## Background and Objectives Pancreatic ductal adenocarcinoma (PDAC) is one of the most extremely aggressive cancers with a poor prognosis after curative resection. L1 cell adhesion molecule (L1CAM) is a 200–220 kDa type I transmembrane glycoprotein of the immunoglobulin superfamily, which has been shown to affect the prognosis of several cancers. No clinicopathological significance of L1CAM expression has been examined at the invasive front of PDAC. In this study, we examined the relationship between L1CAM expression and clinicopathological features in PDAC by immunohistochemistry. ## Methods One hundred seven surgically resected specimens of PDAC were immunohistochemically examined using a monoclonal antibody against L1CAM. ## Results Positive expression of L1CAM was found in 23 of 107 cases with PDAC. In most cases (21/23), L1CAM expression was localized at the invasive front of the tumor tissue. Positive expression of L1CAM was significantly correlated with the histological grade, lymph node involvement, and distant metastasis. In univariate analysis, a positive expression of L1CAM was associated with short overall survival (__P__ = 0.0002), and this was significant

Who reads L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Shinji Tsutsumi; Satoko Morohashi; Yasuyuki Kudo; Harue Akasaka; Hiroshi Ogasawara; Masashi Ono; Kaori Takasugi; Keinosuke Ishido; Kenichi Hakamada; Hiroshi Kijima
Publisher
John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0022-4790)
Published
2011
Language
EN
Field
Medicine (Health Sciences)

More by Shinji Tsutsumi; Satoko Morohashi; Yasuyuki Kudo; Harue Akasaka; Hiroshi Ogasawara; Masashi Ono; Kaori Takasugi; Keinosuke Ishido; Kenichi Hakamada; Hiroshi Kijima

Browse all works by Shinji Tsutsumi; Satoko Morohashi; Yasuyuki Kudo; Harue Akasaka; Hiroshi Ogasawara; Masashi Ono; Kaori Takasugi; Keinosuke Ishido; Kenichi Hakamada; Hiroshi Kijima